Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

NCT00193609 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms, Unknown Primary

Interventions

DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]